Synthesis of poly(ethylene glycol) with sulfadiazine and chlorambucil end groups and investigation of its antitumor activity

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 15, 2003, Pages 2531-2534

  Jia, Zhongfan ^a   Zhang, Haitao ^a   Huang, Junlian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO OMEGA HYDROXYL POLY(ETHYLENE GLYCOL); ALPHA-AMINO-OMEGA-HYDROXYL-POLY(ETHYLENE GLYCOL); ANTINEOPLASTIC AGENT; CHLORAMBUCIL; DRUG CARRIER; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; LEWIS ACID; MACROGOL; MACROGOL DERIVATIVE; POLYMER; SULFADIAZINE; WATER;

ANIMAL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER TRANSPLANTATION; CHEMISTRY; DRUG DESIGN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CANCER; MOLECULAR WEIGHT; MOUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; SAMPLE; SOLUBILITY; SYNTHESIS; TUMOR CELL LINE;

EID: 0037633672     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00470-0     Document Type: Article

References (22)

1. Ouchi T., Hagihara Y., Takahashi K., Takano Y., Igarashi I. Drug Design Discovery. 9:1992;93.
2. Ouchi T., Kuroda H., Hirai K., Ohya Y. Macromol. Rep. A31:1994;1019.
3. Ouchi T., Kuroda H., Hirai K., Ohya Y. J. Bioact. Compat. Polym. 10:1995;51.
4. Ouchi T., Kuroda H., Ohya Y. ACS Symp. Ser. 680:1998;284.
5. Stevens C.D., Quinlin P.M., Meinken M.A., Kock A.M. Science. 112:1950;561.
6. Calvert N., Connors T.A., Ross W.C.J. Eur. J. Cancer. 4:1968;627.
7. Nguyen H.N., Herbert M., Nguyen D.X. J. Labelled Comp. 7:1971;229.
8. Wang. H. Y. Study on Synthesis, Characterization and Properties of Polymeric Targeting Medicines with Sulfadiazine End Group Using Polyethylene Oxide as Matrix; PhD Dissertation Fudan University, Shanghai, 1996.
9. Chen S., Huang Z.H., Huang J.L. Eur. Polym. J. 36:2000;1703.
10. Huang J.L., Wang H.Y., Tian X.Y. J. Polym. Sci. Part A: Polym. Chem. 34:1996;1933.
11. Huang J.L., Chen S., Tan L.S., Wang H.Y. Sci. China (Series B). 41:1998;54.
12. Huang Z.H., Chen S., Huang J.L. J. Appl. Polym. Sci. 73:1999;1379.
13. Chen, S. Studies on Synthesis and Properties of Polymeric Targeting Antitumor Medicines Containing 5-FU and Nitrogen Mustard; PhD Dissertation Fudan University, Shanghai, 1998.
14. Yokoyama M., Okano T., Sakurai Y., Kikuchi A., Ohsako N., Nagasaki Y., Kataoka K. Bioconjugate Chem. 3:1992;275.
15. Huang Z.H., Lin Z.L., Huang J.L. Eur. J. Med. Chem. 36:2001;863.
16. 2OCO) 7.07 (d, 2H, phenyl of chlorambucil), 8.47 (q, 1H, pyrimidyl), 8.81 (d, 2H, pyrimidyl).
17. 2OCO), 6.62 (d, 2H, phenyl), 7.06 (d, 2H, phenyl).
18. Veronese F.M. Biomaterials. 22:2001;405.
19. 2. The top clear solution was got away and 150 μL dimethylsulfoxide (DMSO) was added to dissolve the formazan for each well. After shaken for 10 min by plate shaker, the OD value of each well was measured on an ELISA spectrophotometer at 490 nm.
20. The cytotoxic activity of chlorambucil was evaluated by the same method as that described for the polymer drugs.
21. 50 was calculated by using Bliss method.
22. 6 cells in 0.1 mL were transplanted intracutaneously into the right forelimb of C57 mice (10 mice per group) on day 0. The polymer drugs were sterilized and dissolved in normal saline. The mice bearing the Lewis lung carcinoma cells were treated by tail vein injection with a consecutive (qd×5) schedule at various doses from day 1. From day 6, the volume of the Lewis lung carcinoma was measured to evaluate the in vivo antitumor activity of the polymer drugs.